pharmaphorum43m
BridgeBio poised to challenge Pfizer after Attruby approval
The price is close to the average $225,000 annual cost of Pfizer's drugs, before any discounts or rebates, although BridgeBio ...
BridgeBio: Next Chapter Begins After Attruby Approval
2025 will be a very eventful year for BridgeBio. In addition to the commercial launches of Attruby in the United States, ...
Pharmaceutical Technology43m
FDA approves BridgeBio’s Attruby for ATTR-CM treatment
The US Food and Drug Administration (FDA) has approved BridgeBio Pharma ’s Attruby (acoramidis), an oral transthyretin (TTR) ...
devdiscourse3h
BridgeBio's Breakthrough in Rare Heart Condition Treatment
The U.S. FDA has approved Attruby, a new drug by BridgeBio, for treating a rare heart condition, redefining a market led by ...
STAT2d
BridgeBio wins FDA approval for heart disease drug
The Food and Drug Administration approved on Friday a new medicine from BridgeBio for patients with a progressive heart ...
BioPharma Dive2d
BridgeBio heart drug approved by FDA, setting up battle with Pfizer
The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market ...
US FDA approves BridgeBio's drug for rare heart condition
The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said ...
Pfizer meets amyloidosis rival as BridgeBio wins FDA nod for Attruby
The U.S. FDA late Friday approved BridgeBio Pharma’s (NASDAQ:BBIO) lead asset Attruby for the rare heart disorder ...
BioSpace1d
BridgeBio Wins FDA Approval for ATTR-CM Drug, Launching Competition With Pfizer
BridgeBio secured approval for Attruby Friday, along with the all-important mortality benefit that could give the drug a ...
TipRanks on MSN2d
BridgeBio announces FDA approved Attruby for ATTR-CM patients
Pharma announced that the U.S. Food and Drug Administration approved Attruby, an orally-administered near-complete stabilizer ...
BridgeBio Pharma : FDA Approves Heart Disease Drug 'acoramidis'
BridgeBio Pharma Inc. (BBIO) announced that the U.S. Food and Drug Administration approved Attruby or acoramidis, an ...
BioSpace3h
FDA Action Alert: Applied Therapeutics Awaits Verdict on Rare Disease Therapy
With two decisions originally scheduled for this week already announced, including BridgeBio's approval in ATTR-CM, the ...